African swine fever (ASF) is an acute viral haemorrhagic disease of domestic swine with mortality rates approaching 100 % (Coggins, 1974; Mebus, 1988; Montgomery, 1921) . Devastating ASF outbreaks and a continuing epidemic in the Caucasus region and Russia (2007 to date) highlight the significance of this disease threat (Gogin et al., 2013; Sanchez-Vizcaino et al., 2013) . No ASF vaccine is available, though protection against homologous virus challenge has been observed (Detray, 1957; Gomez-Puertas et al., 1998; Leitao et al., 2001; Lewis et al., 2000; Malmquist, 1963; Ruiz Gonzalvo et al., 1981; Zsak et al., 1996) . Vaccine and disease control progress is hindered by lack of knowledge concerning the ASF virus (ASFV) antigens expressed during infection, responsible for inducing protective immunity, and their diversity in nature.
Although ASFV serological assays used for disease diagnosis have focused on conserved cross-reactive viral proteins (Cubillos et al., 2013; Gallardo et al., 2013) , data based on haemadsorption inhibition (HAI) serological typing indicate distinct antigenic types of ASFV (Coggins, 1968; Detray, 1957; Malmquist, 1963; Pan et al., 1974; Vigario et al., 1970 Vigario et al., , 1974 . Eight ASFV serogroups (SGs) have been identified, although more are likely to exist (Balyshev et al., 1995 (Balyshev et al., , 2010 Malogolovkin et al., 2015a; Sereda & Balyshev, 2011; Sereda et al., 1992; Vishnjakov et al., 1995) . Notably and of particular significance for vaccine development, ASF protective immunity may be serotype-specific, as viruses of homologous HAI SG appear to cross-protect against one another while heterologous viruses do not (Balyshev et al., 1995; Sereda & Balyshev, 2011; Sereda et al., 1992; Vishnjakov et al., 1991; Malogolovkin A., Sereda A., Balyeshev V. and Kolbasov D., unpublished data) . Recently, we have shown that two ASFV-encoded proteins, CD2v (EP402R) and/or C-type lectin (EP153R), are necessary and sufficient for mediating HAI serological specificity (Malogolovkin et al., 2015b) . Here, we test the hypothesis that ASFV CD2v and C-type lectin proteins are responsible in part for the serotype-specific cross-protective immunity observed for ASF and that these viral proteins are significant protective antigens for ASF.
To evaluate ASFV CD2v and C-type lectin proteins as protective antigens, ASF vaccination/challenge experiments using ASFV inter-serotypic recombinant (chimeric) viruses were performed in pigs as previously described (Lewis et al., 2000; Moore et al., 1998; Zsak et al., 1996 Zsak et al., , 1998 (Malogolovkin et al., 2015a) ; and France FK-32/135, an attenuated variant of F-32 obtained by 135 passages of F-32 in porcine bone marrow cell cultures.
Chimeric ASFVs recombinant at the CD2v/C-type lectin gene locus were constructed and characterized as described previously (Malogolovkin et al., 2015b) . Attenuated Congo (KK-262) and France (FK-32/135) ASFVs were used as backbones to construct ASFV recombinants (Congo France CD2v/Lectin and France Congo CD2v/Lectin , respectively) in which native CD2v/C-type lectin genes were deleted and replaced by those from the heterologous, virulent virus. Congo K49 and France F-32 exhibited indel and amino acid divergence (35 and 47 % pairwise divergence in CD2v and C-type lectin proteins, respectively) as described previously between isolates of different SGs (Malogolovkin et al., 2015b) . Briefly, chimeric ASFVs were obtained by homologous recombination following infection with parental virus and transfection with recombination plasmids (Malogolovkin et al., 2015b) . Recombination plasmids were constructed using arm sequences homologous to the backbone virus to flank the C-type lectin/CD2v locus (approximately 600 bp upstream of C-type lectin protein start and 600 bp downstream of CD2v stop codon), the heterologous strain C-type lectin and CD2v gene locus (C-type lectin start codon to CD2v stop codon), and a GFP reporter gene driven by the ASFV P72 capsid protein gene promoter (i.e. homologous left arm, heterologous C-type lectin/CD2v locus, P72-GFP, homologous right arm). Recombinants were selected by limiting dilution and GFP expression under a UV microscope. Viral purity and recombinant sequence fidelity was verified by PCR and DNA sequencing. ASFV chimeric viruses exhibited normal growth characteristics and haemadsorption in both macrophage and bone marrow cell cultures.
For animal vaccination/challenge experiments, pigs (30-35 kg) were vaccinated and then challenged in four independent experiments detailed below. Survival rate and timeto-death were recorded. Clinical signs of ASF [fever (a rectal temperature greater than or equal to 104 F), anorexia, lethargy, shivering, cyanosis and recumbency] were monitored daily. Blood samples were collected at regular intervals postvaccination and for 30 days post-challenge. Quantitative PCR of ASFV in blood samples was performed as previously described (King et al., 2003) . Serological assays were performed using serum collected just prior to challenge infection. HAI assays were performed in swine macrophages as previously described (Ruiz Gonzalvo et al., 1996; Vishnjakov et al., 1995) . Indirect ASFV ELISA assays were performed using procedures recommended by the manufacturer (IDVet). Challenge data with multiple data points per group were assessed by one-way ANOVA, or KruskalWallis one-way ANOVA on ranks if data failed ShapiroWilk normality testing, and by Tukey's or Dunn's multiple comparison tests between significant groups as implemented in SigmaPlot v11 (Systat Software). Statistically significant results are noted in the tables and text.
The first two experiments were designed to test the necessity of homologous CD2v/C-type lectin for inducing a protective immune response. Experiments 3 and 4 were designed to test whether homologous CD2v/C-type lectin alone was sufficient for inducing protection when expressed by a heterologous ASFV. These data indicate that induction of protective ASFV immunity depends on homologous CD2v/C-type lectin. The solid protection induced against virulent Congo virus challenge by immunization with homologous, attenuated KK-262 was lost when native CD2v/C-type lectin genes were replaced with those from a heterologous virus, France (F-32, SG 4). Thus, under these experimental conditions À1 ], with SE in parentheses. #Animals demonstrating viral load in blood at any day sampled post-challenge as a percentagfe of group total (%), and mean maximum viral load in these animals (Load), with SE in parentheses. Percentage of animals in group developing positive antibody titres using IDVet ELISA.
† †Percentage of animals in group developing HAI antibody titre >1 : 2 against ASFV strain Congo.
using the highly virulent Congo strain of ASFV, homologous ASFV CD2v and/or C-type lectin proteins are necessary for inducing protective immunity.
Immunization with homologous ASFV CD2/Lectin proteins affects ASF disease course. To determine if serotypespecific CD2v and C-type lectin proteins are sufficient for mediating ASFV protective immunity, pigs were vaccinated with France Congo CD2v/Lectin , an attenuated France strain (FK-32/135)-based chimeric virus in which native CD2v/Ctype lectin genes were deleted and replaced by those from the heterologous Congo virus (K-49), and then challenged with virulent Congo K49 ( Table 2) .
As expected, animals immunized with Congo-attenuated (KK-262) virus were solidly protected from challenge with virulent Congo K49 while animals immunized with the heterologous France-attenuated (FK-32/135) virus were not (Table 2 , experiment 3). Lack of heterologous protection included rapid onset of fever and other ASF clinical signs and high-titred viraemic loads. Homologous protective immunity induced by KK-262 was associated with pre-challenge HAI titres to Congo virus ranging from 1 : 4 to 1 : 16.
Immunization with France
Congo CD2v/Lectin failed to fully protect animals from challenge with virulent Congo K49 (Table 2 ). However, in experiment 4 where multiple booster immunizations were administered, a degree of partial protection was observed in France Congo CD2v/Lectin -vaccinated animals as significantly delayed time-to-death (approximately 3 days), onset of fever, and onset of viraemia (Table 2 , experiment 4). Notably, the HAI serological response to Congo virus observed in experiment 4 France Congo CD2v/Lectin -vaccinated animals (seven of eight animals positive, with titres ranging from 1 : 4 to 1 : 16) correlated with the delay in disease onset. Since France-attenuated (FK-32/135) and France Congo CD2v/Lectin viruses differ only at the CD2v/C-type lectin gene locus, the partial protective effect observed here is likely due to host responses to the homologous Congo CD2v/C-type lectin proteins encoded in the France Congo CD2v/Lectin chimera.
Results presented here provide compelling evidence that ASFV CD2v (EP402R) and/or C-type lectin (EP153R) proteins are important for homologous protective immunity and thus significant ASFV protective antigens (Table 1) . Further, the fact that the solid protection afforded by immunization with the Congo-attenuated (KK-262) strain, an SG2 virus, was lost when the Congo CD2v/C-type lectin genes were replaced with those from a virulent France strain (F32), an SG4 virus, directly supports the emerging concept that ASF protective immunity is HAI serotype-specific (Balyshev et al., 1995; Sereda & Balyshev, 2011; Sereda et al., 1992; Vishnjakov et al., 1991; Malogolovkin et al., unpublished data) .
Immunization of animals with France Congo CD2v/Lectin virus did not fully protect animals from virulent Congo virus challenge (Table 2) . Thus, while these proteins are important for protection, they do not appear to be alone sufficient under the experimental immunization protocols used in these experiments. It is known that ASFV HAI antibodies appear late and at relatively low titre during infection and that virulence of the infecting viral strain may influence HAI antibody production (Malmquist, 1963; Ruiz Gonzalvo & Coll, 1993; Ruiz Gonzalvo et al., 1986; Vigario et al., 1970) . Conceivably, the immunization schedule used here and/or the virulence properties of the France-attenuated (FK-32/135) strain used to express the Congo CD2v/C-type lectin genes were not adequate to obtain appropriate/protective immune responses (humoral and cellular) in France Congo CD2v/Lectin -immunized pigs. Alternatively, host responses directed against additional Congo viral proteins may be needed to achieve full protection.
Chimeric viruses used in these experiments contained heterologues of both CD2v and C-type lectin proteins. The actual contribution of the individual proteins to the results obtained remains to be determined. ASFV CD2v has been implicated (Ruiz Gonzalvo & Coll, 1993; Zsak et al., 2010) . Additionally, M-II antibody titres in vaccinated/ convalescent animals appeared to correlate with protection from challenge (Knudsen et al., 1987; Ruiz Gonzalvo et al., 1986) . A role for two T-cell epitopes located on CD2v in protective immunity also has been speculated (Argilaguet et al., 2012 (Argilaguet et al., , 2013 . The significance of the ASFV C-type lectin protein for protective immunity remains to be determined, although its strong serotype-specific association suggests potential involvement.
Results from experiments 1 and 2 also suggest a lesser role for other, yet to be identified, ASF viral proteins in inducing protective host responses. ASF disease course for Congo France CD2v/Lectin virus-vaccinated animals was affected as compared with mock-vaccinated animals. Delays in viraemia onset and magnitude were observed in Congo France CD2v/Lectin virus-vaccinated groups (Table 1) . A number of additional ASFV proteins have been suggested to play roles in protection although none has been shown to be sufficient for inducing solid protective immunity in the pig (Barderas et al., 2001; Gomez-Puertas et al., 1998; Lacasta et al., 2014; Neilan et al., 2004) .
Notably, prior results (Ruiz Gonzalvo & Coll, 1993) and those reported here indicating an important role for CD2v and/or C-type lectin in ASF protective immunity appear discrepant with studies indicating that attenuated non-haemadsorbing ASFV viruses (OURT88/3 and NHP68), which presumably lack CD2v/C-type lectin proteins, protected pigs from challenge with virulent viruses (Boinas et al., 2004; Leitao et al., 2001; Oura et al., 2005) . Both OURT88/3 and NHP68 (probably the same virus isolated 20 years apart in Portugal) contained N-terminal-truncating mutations in both CD2v and C-type lectin genes, likely affecting their expression, membrane localization, and the observed non-haemadsorbing phenotype (Portugal et al., 2015; Rowlands et al., 2009) . Interestingly and of potential significance here, internal in-frame methionines (ATGs) are present in both ORFs of OURT88/3 and NHP68, conceivably allowing expression of intracellular C-type lectin and CD2v protein fragments containing previously identified HAI signature domains (Malogolovkin et al., 2015b) . Even with relatively inefficient translation of these internally-initiated viral RNAs, sufficient protein may be available in the infected cell for peptide processing and viral epitope presentation to the host's immune system. Alternatively, discrepancies among these data simply may reflect significant differences in aspects of the vaccination-challenge experimental design and/or the virulence of the ASFV challenge viruses employed in the studies.
In summary, we have demonstrated that ASFV serotypespecific proteins CD2v and/or C-type lectin are important for homologous protection against ASFV. Thus, these viral proteins represent significant protective antigens for ASFV that should be further evaluated and targeted for vaccine design and development.
